Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Int J Neuropsychopharmacol. 2009 Sep 15;13(4):411–420. doi: 10.1017/S1461145709990587

Figure 4.

Figure 4

Medicated MDD subjects vs controls. Immunoblots of GAD-67 (A), GAD-65 (C) and tubulin from two representative pairs of control and medicated MDD subjects used in the analysis; (B) amount of GAD-67 immunoreactivity from control (n=8) and depressed (n=8) subjects; (D) amount of GAD-65 immunoreactivity from control (n=8) and depressed (n=8) subjects. Normalized optical density values for the individual subjects (circles) and mean values (horizontal lines) are presented.